COVID-19 Immunity Testing: A Passport to Inequity
By Françoise Baylis and Natalie Kofler,
Issues in Science and Technology
| 04. 29. 2020
In an already heavily stratified society, the introduction of immunity passports is ethically problematic. They would not only exacerbate current inequities but also create a novel layer of biological inequity.
As COVID-19 case numbers start to plateau in various places, some governments are now focusing on how best to ease restrictions and reopen the economy. In the absence of herd immunity for the population—for which the threshold may be as high as 82%—next steps are not obvious.
Recently, some have touted “immunity passports” for people who have survived infection with SARS-CoV-2 (the novel coronavirus that causes COVID-19) and tested positive for SARS-CoV-2 antibodies. Under this proposal, citizens deemed immune to the virus through serological testing (a type of blood test) could be freed from current restrictions and allowed to return to work. According to media reports, Chile is poised to become the first country to issue some kind of immunity cards. Others considering this option include Australia, Germany, Italy, the United Kingdom, and the United States.
In an already heavily stratified society, the introduction of immunity passports is ethically problematic. They would not only exacerbate current inequities but also create a novel layer of biological inequity—one based on a potentially ineffective measure of immunity.
Infection with...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
By Mustapha Bature Sallama, Modern Ghana | 06.11.2026
In much of West Africa, a woman who cannot bear children does not merely face a medical condition. She faces a verdict. Her marriage may unravel. Her community may turn cold. Her identity, in a social order that ties womanhood...
By Anna Rogers, Mother Jones | 06.19.2026
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
